Evaluation and Management of Mildly Elevated Hemoglobin and Hematocrit in Females
For a female with mildly elevated hemoglobin and hematocrit, first determine if values exceed the diagnostic threshold for polycythemia vera (hemoglobin >16.5 g/dL), then check serum erythropoietin level and consider JAK2 mutation testing if PV is suspected.
Defining "Mildly Elevated"
The critical first step is determining whether the elevation warrants investigation for polycythemia vera versus representing physiologic variation:
- PV diagnostic threshold: Hemoglobin >16.5 g/dL in women 1
- Alternative PV consideration: Hemoglobin >15 g/dL if associated with a documented sustained increase of ≥2 g/dL from baseline that cannot be attributed to iron deficiency correction 1
- Normal range consideration: Values above the 95th percentile for age, sex, and race-adjusted reference ranges warrant evaluation 2
Initial Diagnostic Algorithm
Step 1: Assess Clinical Context
Look specifically for:
- Iron deficiency: Microcytosis, low ferritin (iron deficiency can mask PV by lowering hemoglobin/hematocrit) 1, 2
- PV-related features: Thrombocytosis, leukocytosis, splenomegaly, aquagenic pruritus, unusual thrombosis (including Budd-Chiari syndrome), erythromelalgia 2
- Secondary causes: Chronic hypoxia from lung disease, smoking, sleep apnea, high altitude residence 2
Critical pitfall: Iron deficiency can confound PV diagnosis by lowering hemoglobin levels. In routine practice, you should not be prevented from making a working diagnosis of PV in the presence of iron deficiency, even if WHO criteria are not formally met 1. However, for research purposes, formal PV diagnosis requires demonstrating WHO criteria after iron replacement.
Step 2: Serum Erythropoietin Level
- Low EPO: Highly suggestive of PV (>90% specificity), though sensitivity is only ~70% 2
- Normal EPO: Does not exclude PV; proceed with further evaluation if clinical suspicion remains 2
- Elevated EPO: Makes PV unlikely; suggests secondary polycythemia 2
Step 3: JAK2 Mutation Testing
If hemoglobin >16.5 g/dL or if PV-related features are present with borderline-high values:
- JAK2 V617F mutation is present in the majority of PV cases 1
- JAK2 exon 12 mutations should be considered if V617F is negative 1
Step 4: Bone Marrow Biopsy (When Indicated)
Required for definitive PV diagnosis when:
- Hemoglobin >16.5 g/dL AND JAK2 mutation positive (need 1 minor criterion) 1
- Hemoglobin >16.5 g/dL but JAK2 mutation negative (need 2 minor criteria including bone marrow showing hypercellularity with trilineage growth) 1
Management Based on Findings
If PV is Diagnosed:
Refer to hematology for management including phlebotomy, aspirin, and potentially cytoreductive therapy.
If Values Are Below PV Threshold (<16.5 g/dL):
- Repeat testing in 3 months if no PV-related features are present 2
- Investigate secondary causes: Smoking cessation counseling, sleep study if indicated, pulmonary function testing if respiratory symptoms present
- Consider altitude: Normal ranges are higher at altitude (e.g., at 4000m, normal female hematocrit can be 41-56%) 3
If Iron Deficiency Is Present:
- Treat with oral iron first (intermittent dosing is as effective as daily with fewer side effects) 4
- Reassess hemoglobin/hematocrit after iron repletion to unmask potential underlying PV 1, 2
Key Clinical Caveats
- Do not order red cell mass measurement routinely: It is costly, rarely changes management, and can miss PV cases at the lower end of the distribution 2
- Hematocrit >60% almost always indicates increased red cell mass unless obvious clinical hemoconcentration is present 2
- Document baseline values: A sustained increase of ≥2 g/dL hemoglobin from an individual's baseline warrants investigation even if absolute values are not dramatically elevated 1
The evidence strongly supports this algorithmic approach, with 1 providing the most recent WHO diagnostic criteria revision and 2 offering the comprehensive diagnostic algorithm that prioritizes practical, cost-effective testing over red cell mass measurement.